NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Akari Therapeutics, Plc (AKTX) Stock Analysis

Akari Therapeutics, Plc (AKTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AKTX

$8.76

−$0.53 (−5.71%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AKTX with… →

AKTX Key Statistics

As of Oct 21, 2026
Trading
Open
$9.29
Previous Close
$9.29
Day's Range
8.76–9.94
52-Week Range
3.02–33.60
Volume
30.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.44
Valuation
Market Cap
$20.02M
EPS (ttm)Profit attributable to each share over the last twelve months.
0.00
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$17.30M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.29M
1-Year Return
−70.92%
Dividend and dates
Avg Volume
61.25K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AKTX closed at $8.76, −70.92% over 1 year.

Akari Therapeutics, Plc (AKTX) has a market capitalization of $20.02M.

In fiscal 2025, AKTX reported revenue of $0.00.

AKTX Stock Return by Calendar Year

Akari Therapeutics, Plc (AKTX) 10-year return: what $10,000 became

1 year
$10,000 $2,908
−70.92%
5 years
$10,000 $65
−99.35%
10 years
$10,000 $14
−99.86%

If you had invested $10,000 in Akari Therapeutics, Plc (AKTX) 10 years ago, at the close on October 21, 2016, it would have been worth $14 at the close on October 21, 2026: −99.86% in total, −48.35% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−24.22%
2025−76.31%
2024−60.90%
2023−66.81%
2022−68.67%
2021−18.92%
2020+5.71%
2019+11.46%
2018−63.74%
2017−38.49%
2016 (partial year)−26.44%

As of October 21, 2026.

AKTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$17.30M—
2024$0.00−$19.79M—
2023$0.00−$10.01M—
2022$0.00−$17.75M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$12.10M−$17.30M—
2024$0.00—−$16.65M−$19.79M—
2023$0.00—−$16.81M−$10.01M—
2022$0.00—−$23.09M−$17.75M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Akari Therapeutics, Plc (AKTX) is capitalised at $20.02M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 5 employees.

Over the past 52 weeks the price has ranged from $3.02 to $33.60. AKTX last closed at $8.76 on October 21, 2026. That is −$0.53 (−5.71%) against the previous close. The latest close sits 190.55% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $17.30M. Earnings per share on a trailing basis come to 0.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

Over the trailing twelve months the total return is −70.92%. Across 10 years the annualized return works out at −48.35%. The reported beta is 1.44. Annualized volatility over the trailing 10 years is 146.58%.

Growth & Income

No dividend is on file for AKTX.

2026 is still running; the total return is −24.22% year to date. The strongest complete calendar year on file is 2019 at +11.46%; the weakest is 2025 at −76.31%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Akari Therapeutics, Plc (AKTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Akari Therapeutics, Plc AKTX $20.02M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Akari Therapeutics, Plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Akari Therapeutics, Plc

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

Visit website →